Ascendis' Skytrofa (lonapegsomatropin-tcgd) Receives the US FDA's Approval for Pediatric Growth Hormone Deficiency
Shots:
- The approval is based on the P-III heiGHt trial evaluating Skytrofa (qw) vs somatropin in 161 treatment-naïve children ≥aged 1yrs. with GHD who have growth failure due to inadequate secretion of endogenous GH
- The study met its 1EPs i.e.- non-inferiority in AHV & showed a higher AHV @52wks.- no serious AEs or discontinuations related to Skytrofa were observed
- Skytrofa is the 1st product developed by using Ascendis’ TransCon technology platform & is being evaluated in P-III trials for pediatric GHD in Japan and Greater China. The therapy will be available in the US imminently by a full suite of patient support programs
| Ref: GlobeNewswire | Image: PR Newswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com